{
  "id": "acute-lymphoblastic-leukemia",
  "title": "Acute Lymphoblastic Leukemia",
  "lang": "en",
  "source_lang": "en",
  "summary": "Acute lymphoblastic leukemia is a rapidly progressing cancer of immature lymphoid cells, classified and treated according to lineage, genetics, and treatment response.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Acute lymphocytic leukemia",
    "ALL",
    "Acute lymphoid leukemia"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/acute-lymphoblastic-leukemia/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/acute-lymphoblastic-leukemia/",
      "json": "https://aiwiki.page/zh/acute-lymphoblastic-leukemia.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Acute lymphoblastic leukemia (ALL) is a cancer in which immature cells committed to lymphoid development multiply abnormally, principally in the bone marrow and blood. These malignant cells, called lymphoblasts, interfere with normal blood-cell production and may infiltrate organs and tissues. ALL is the most common childhood cancer, but it also occurs in adolescents and adults, including older adults, in whom its biological characteristics and treatment outcomes differ substantially.\n\nALL is not a single molecular disease. Its major forms arise from precursors of B lymphocytes or T lymphocytes, and each contains genetically distinct subgroups. Diagnosis combines examination of blood and marrow with immunophenotyping and genetic testing. Treatment generally involves several phases of systemic therapy, treatment directed at the central nervous system, and repeated measurement of residual leukemia. Molecularly targeted drugs, antibody-based therapies, cellular immunotherapies, and stem-cell transplantation have increasingly changed how particular subgroups are managed.\n\nThe disease became a central model for curative combination chemotherapy during the twentieth century. Contemporary treatment cures most children in well-resourced treatment programs, although outcomes remain less favorable for many adults and for some genetic subtypes. Important continuing challenges include resistant disease, relapse, treatment toxicity, and unequal access to diagnosis and sustained supportive care."
    },
    {
      "heading": "Cellular origin and molecular classification",
      "text": "Normal lymphocyte development proceeds through stages in which immature blood-forming cells acquire the receptors and functions required for immune responses. ALL develops when genetic alterations disrupt this differentiation process while permitting abnormal survival and proliferation. The resulting lymphoblasts usually retain molecular and surface features of their developmental stage but do not function as mature immune cells. Their accumulation suppresses normal red-cell, platelet, and white-cell production.\n\nThe two principal categories are B-lymphoblastic leukemia and T-lymphoblastic leukemia. B-lineage disease accounts for approximately 80–85% of childhood ALL and most adult cases. T-lineage disease is proportionally more frequent among adolescents and young adults, particularly males. B-lymphoblastic leukemia and B-lymphoblastic lymphoma, like their T-lineage counterparts, represent different clinical presentations of closely related biological diseases. Leukemia denotes predominant marrow and blood involvement; lymphoma denotes a predominantly tissue-based presentation. The boundary is operational rather than a fundamental biological separation.\n\nGenetic classification is particularly developed in B-lineage ALL. Recognized groups include disease with ETV6::RUNX1, BCR::ABL1, KMT2A rearrangements, TCF3::PBX1, high hyperdiploidy, and hypodiploidy, among others. High hyperdiploidy generally involves 51–65 chromosomes. ETV6::RUNX1-positive and high-hyperdiploid ALL are common childhood subgroups and often have favorable outcomes with contemporary therapy. KMT2A-rearranged disease is especially important in infants, whereas low-hypodiploid disease carries distinct biological and clinical risks. Newer classifications also recognize groups defined by alterations involving genes such as DUX4, MEF2D, ZNF384, and NUTM1.\n\nThe BCR::ABL1 fusion results from the Philadelphia chromosome, usually generated by the translocation \\(t(9;22)\\). Its protein product has constitutive tyrosine-kinase activity, driving growth and survival signals. Although this fusion also characterizes chronic myeloid leukemia, its occurrence in ALL defines a distinct treatment setting. Philadelphia chromosome–like, or BCR::ABL1-like, ALL has a related gene-expression profile without the BCR::ABL1 fusion itself. This heterogeneous category includes several kinase-activating lesions, some of which provide potential therapeutic targets.\n\nT-lineage ALL frequently involves alterations in NOTCH1 signaling, cell-cycle control, and transcriptional programs governing T-cell development. Early T-cell precursor ALL has an immature immunophenotype with some stem-cell or myeloid-associated features. Its clinical behavior depends on treatment context and response; it is not adequately characterized by a single universal prognosis. Across both lineages, molecular classification increasingly complements morphology rather than merely adding descriptive detail."
    },
    {
      "heading": "Epidemiology and causes",
      "text": "The incidence of ALL has a characteristic age distribution: a prominent peak in early childhood, lower rates through much of adult life, and a subsequent increase in older age. In the United States, the overall annual incidence is approximately 1.5–2 cases per 100,000 people, although estimates vary by population and reporting period. Childhood incidence peaks at about 2–5 years of age. ALL accounts for roughly three quarters of childhood leukemias and about one quarter of cancers diagnosed in children.\n\nRates differ by sex, ancestry, geography, and age. Males have a modestly higher incidence than females, with a more pronounced male predominance in T-lineage disease. In United States registries, childhood ALL incidence is higher among Hispanic children than among several other major population groups. These patterns reflect interacting inherited, environmental, and demographic influences; population categories do not establish a single biological explanation. International comparisons are also affected by incomplete registration and missed diagnoses.\n\nMost patients have no identifiable cause. Acquired alterations in DNA are central to leukemia development, but the circumstances producing them are usually unknown. High-dose ionizing radiation is an established leukemia risk factor. ALL can also occur after previous cancer treatment, although therapy-related ALL is much less common than therapy-related acute myeloid leukemia or myelodysplastic syndromes. Many proposed associations involving household exposures or environmental agents remain difficult to separate from bias, chance, and confounding.\n\nInherited susceptibility accounts for a minority of cases. Children with Down syndrome have a substantially increased risk of ALL. Rare pathogenic variants affecting genes such as ETV6, PAX5, IKZF1, and TP53 can predispose to lymphoid malignancy. Common inherited variants, including variants near ARID5B and IKZF1, also influence population-level susceptibility without determining whether an individual will develop leukemia. A somatic alteration found in leukemic cells is therefore not automatically evidence of an inherited condition.\n\nStudies of identical twins and archived newborn blood samples show that initiating genetic lesions in some childhood B-ALL cases arise before birth. An initiating clone may persist for years and never progress. Additional acquired changes are usually required for overt leukemia. Models involving abnormal immune responses to common infections after limited early microbial exposure have been proposed for some childhood B-ALL subtypes, but they do not establish a specific infectious cause. ALL is not contagious, and no population screening or preventive intervention has been established for children at ordinary risk."
    },
    {
      "heading": "Clinical manifestations and disease distribution",
      "text": "The principal manifestations of ALL result from marrow failure, tissue infiltration, and the metabolic consequences of rapid cell turnover. Symptoms often evolve over several weeks, although the interval varies. They are not specific to leukemia: common infections and nonmalignant blood disorders can produce similar findings. Some patients appear acutely ill at diagnosis, while others have relatively subtle symptoms despite extensive marrow involvement.\n\nReduced red-cell production causes anemia, producing pallor, fatigue, reduced exercise tolerance, or breathlessness. Inadequate platelet production can cause easy bruising, petechiae, nosebleeds, or other mucosal bleeding. Reduced numbers or impaired function of normal white cells increase susceptibility to infection. Fever may reflect infection, leukemia-associated inflammation, or both. A high total white-cell count does not imply effective immune protection, because many circulating cells may be malignant blasts.\n\nExpansion within marrow can cause bone or joint pain, sometimes producing a limp or reluctance to walk in children. Enlargement of lymph nodes, the liver, or the spleen is common. T-lineage ALL may produce a mass in the mediastinum, related to thymic involvement. Such a mass can compress the airway or major veins, causing respiratory symptoms or superior vena cava obstruction. This anatomical pattern also affects the safety of sedation and diagnostic procedures.\n\nThe central nervous system is an important site of disease even when neurological symptoms are absent. Leukemic cells can enter the meninges and cerebrospinal fluid. Symptomatic involvement may cause headache, vomiting, cranial nerve abnormalities, or other neurological findings, but most patients do not have overt neurological disease at presentation. The testes are another recognized site of involvement and relapse. Overt testicular disease is relatively uncommon at initial diagnosis.\n\nMarkedly elevated white-cell counts can occasionally produce leukostasis, in which abnormal cells impair microvascular blood flow. This complication is less frequent in ALL than in acute myeloid leukemia at comparable counts, but it can cause serious respiratory or neurological dysfunction. Rapid breakdown of leukemia cells can also produce tumor lysis syndrome, sometimes before treatment begins. Release of intracellular potassium, phosphate, and nucleic-acid breakdown products can lead to electrolyte disturbances, acute kidney injury, cardiac arrhythmias, and seizures. Clinical severity therefore depends not only on the apparent volume of leukemia but also on its distribution and physiological effects."
    },
    {
      "heading": "Diagnostic investigation and differential diagnosis",
      "text": "Investigation usually begins with a complete blood count and examination of a peripheral blood smear. Typical findings include anemia, thrombocytopenia, and circulating blasts, but the white-cell count may be high, normal, or low. The absence of visible blasts in peripheral blood does not exclude ALL. Definitive characterization generally requires marrow aspiration, often accompanied by a marrow biopsy, together with lineage and genetic studies.\n\nMicroscopy identifies blast morphology but cannot reliably establish all clinically important subtypes. Historically, the French–American–British system separated lymphoblasts into L1, L2, and L3 morphological categories. This system has largely been replaced by classifications integrating immunophenotype and genetics. The mature B-cell disease historically associated with L3 morphology is now generally classified with Burkitt lymphoma/leukemia rather than precursor B-ALL. In current acute-leukemia practice, a marrow blast proportion around 20% is commonly used as a diagnostic threshold, while some leukemia-versus-lymphoma conventions use 25%; classification requires the complete pathological context.\n\nFlow cytometry establishes the pattern of proteins expressed by abnormal cells. B-lineage blasts commonly express CD19, cytoplasmic CD79a, and CD22, with variable CD10 and other markers. Cytoplasmic or surface CD3 is central to identifying T-lineage differentiation. Terminal deoxynucleotidyl transferase is frequently expressed by immature lymphoblasts. Interpretation depends on combinations and expression patterns rather than a single marker, because aberrant expression of myeloid-associated or other antigens can occur.\n\nChromosome analysis, fluorescence in situ hybridization, polymerase-chain-reaction assays, and sequencing identify genetic subgroups and actionable abnormalities. Rapid detection of BCR::ABL1 is especially important because it changes treatment. Genetic results also establish markers that may be followed during therapy. Some findings, such as apparent hyperdiploidy, require careful interpretation: a doubled hypodiploid clone can resemble a more favorable chromosome pattern unless additional testing identifies its origin.\n\nAssessment of disease extent includes cerebrospinal-fluid examination obtained by lumbar puncture when clinically appropriate. Blood chemistry evaluates renal and hepatic function, uric acid, electrolytes, and markers of cell turnover. Imaging is selected according to presentation rather than used as a universal solid-tumor staging system. The differential diagnosis includes acute myeloid leukemia, mixed-phenotype acute leukemia, lymphoblastic lymphoma, reactive lymphoid proliferations, marrow failure disorders, and other malignancies involving marrow. Distinguishing Philadelphia-positive ALL from chronic myeloid leukemia presenting in lymphoid blast phase can require clinical history, marrow findings, and detailed molecular evaluation."
    },
    {
      "heading": "Risk assessment and measurable residual disease",
      "text": "ALL treatment is organized around risk of treatment failure and the patient’s ability to tolerate therapy. Unlike many solid tumors, ALL is not principally assigned a stage according to local extension and distant metastasis. It is treated as a systemic disease from diagnosis. Risk classification instead combines age, presenting white-cell count, lineage, genetics, extramedullary involvement, and the speed and depth of treatment response.\n\nA widely used initial classification for childhood B-ALL defines standard risk by age from 1 to under 10 years and a presenting white-cell count below \\(50 \\times 10^9/L\\). Children outside these limits are initially categorized as higher risk, although subsequent biological and response information can substantially modify treatment assignment. Infants, especially those with KMT2A-rearranged disease, form a distinct clinical group. Adults require different frameworks because age-related biology, comorbidities, and treatment tolerance alter both relapse risk and treatment-related mortality.\n\nMeasurable residual disease (MRD), formerly commonly called minimal residual disease, is leukemia detectable below the sensitivity of routine microscopy. A marrow sample may look morphologically normal while still containing a substantial number of leukemic cells. MRD therefore distinguishes a conventional remission from a deeper response. Its measurement is among the strongest predictors of relapse in both childhood and adult ALL, and it often has greater practical importance than individual features present at diagnosis.\n\nMRD can be measured by multiparameter flow cytometry, molecular tracking of immunoglobulin or T-cell receptor rearrangements, fusion-transcript assays, and next-generation sequencing. Common validated flow and molecular methods reach sensitivities around one leukemic cell in 10,000 normal cells, or \\(10^{-4}\\), under appropriate conditions. Some sequencing-based methods can detect lower levels, approaching \\(10^{-6}\\), when sufficient suitable material is available. These figures describe assay capability, not interchangeable clinical thresholds. Sample quality, marrow cellularity, target stability, and laboratory validation affect interpretation.\n\nProtocols commonly assess MRD at the end of induction and at later treatment milestones. Persistent or rising MRD can lead to treatment intensification, immunotherapy, or consideration of transplantation, depending on disease subtype and protocol. An MRD-negative result means that leukemia was not detected above the assay’s validated limit; it does not establish that every leukemic cell has been eliminated. Interpretation is also disease-specific. For example, BCR::ABL1 transcript measurements may need to be considered alongside lymphoid-clone assays because the fusion can sometimes be present in cells outside the lymphoblast population."
    },
    {
      "heading": "Multi-phase chemotherapy and central nervous system treatment",
      "text": "Conventional ALL therapy uses drugs with different mechanisms and toxicity profiles in a planned sequence. The major phases are remission induction, consolidation or intensification, and maintenance, although terminology and scheduling differ among protocols. Treatment commonly lasts about two to three years in chemotherapy-based regimens, with substantial variation by age, risk group, and treatment strategy. Newly developed targeted and immune-based regimens do not always follow this traditional duration or structure.\n\nInduction aims to restore normal marrow function and produce a complete remission. Common components include a corticosteroid, such as dexamethasone or prednisone, vincristine, and asparaginase, with an anthracycline added in many regimens. Corticosteroids induce lymphoblast death; vincristine disrupts microtubules; anthracyclines damage DNA and interfere with topoisomerase II. Asparaginase depletes circulating asparagine, exploiting the limited capacity of many lymphoblasts to synthesize enough of this amino acid. Drug selection and intensity differ substantially between pediatric, adult, and older-adult protocols.\n\nConsolidation and intensification address leukemia that survives induction. Regimens may include methotrexate, mercaptopurine, cyclophosphamide, cytarabine, and additional courses of induction-associated agents. Some pediatric protocols incorporate delayed intensification, a later block designed to reproduce selected features of early therapy. Maintenance usually relies on repeated exposure to mercaptopurine and methotrexate, sometimes with additional intermittent drugs. Its prolonged duration is a distinctive feature of ALL treatment and reflects evidence that early morphological remission alone does not reliably prevent recurrence.\n\nThe central nervous system requires specific treatment because systemic drug exposure there can be limited by anatomical and pharmacological barriers, including the blood–brain barrier. Intrathecal chemotherapy delivers drugs directly into cerebrospinal fluid, commonly methotrexate alone or in combination with cytarabine and a corticosteroid. Systemic drugs with useful central nervous system activity also contribute. Cranial radiation therapy, once used widely for prevention, has been reduced or omitted in many modern protocols because of neurocognitive, endocrine, and second-cancer risks. It remains part of selected treatment settings.\n\nAge strongly influences regimen design. Pediatric-inspired regimens have improved outcomes for many adolescents and young adults, but their tolerability varies with age and comorbidity. Older adults have higher risks from intensive chemotherapy, prompting lower-intensity combinations and greater incorporation of targeted or immune therapies. Pharmacogenomics also informs treatment: inherited variation in TPMT and NUDT15 affects thiopurine metabolism and the risk of profound marrow suppression. Protocol-based dose adjustment and toxicity assessment are therefore integral to treatment, rather than departures from a uniform drug schedule."
    },
    {
      "heading": "Targeted therapy, immunotherapy, and transplantation",
      "text": "The identification of molecular drivers and lineage-specific antigens has expanded treatment beyond nonspecific cytotoxic drugs. In Philadelphia chromosome–positive ALL, tyrosine-kinase inhibitors suppress BCR::ABL1 signaling. Agents used in this setting include imatinib, dasatinib, and ponatinib. Their incorporation transformed a historically very high-risk subtype. Drug choice and treatment sequence depend on the protocol, patient characteristics, resistance mutations, and toxicity profile. Some contemporary strategies combine a kinase inhibitor with immunotherapy and substantially reduce conventional chemotherapy exposure.\n\nAntibody-based therapies exploit proteins on B-lineage blasts. Rituximab, a monoclonal antibody directed against CD20, is incorporated into some regimens for CD20-positive B-ALL. Blinatumomab is a bispecific antibody construct that links CD19-positive leukemia cells to CD3-positive T cells, enabling T-cell-mediated killing. It has established roles in relapsed or refractory B-ALL and in MRD-positive disease, and randomized evidence has supported its incorporation into some frontline treatment programs. Its important toxicities include cytokine release syndrome and neurological adverse effects.\n\nInotuzumab ozogamicin is an antibody–drug conjugate targeting CD22. After binding and internalization, its attached cytotoxic component damages DNA. It can induce remission in relapsed or refractory B-ALL and is also used in selected lower-intensity treatment approaches. A major complication is hepatic sinusoidal obstruction syndrome, particularly in relation to subsequent transplantation. Consequently, the sequence and cumulative exposure of different treatments have clinical importance beyond whether each drug can produce an initial response.\n\nCAR T-cell therapy uses T cells engineered to express a chimeric antigen receptor, usually directed against CD19 in B-ALL. It can produce deep remissions in heavily pretreated patients. Licensed products and eligible age groups differ across jurisdictions. Major risks include cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, prolonged cytopenias, and depletion of normal B cells. Relapse can occur through loss or alteration of the target antigen, inadequate persistence of engineered cells, or survival of resistant disease.\n\nAllogeneic hematopoietic stem-cell transplantation combines conditioning treatment with replacement of blood-forming cells from a donor. Its antileukemic activity includes the graft-versus-leukemia effect, but it carries risks of infection, organ injury, and graft-versus-host disease. It is used selectively, particularly for persistent MRD, certain high-risk presentations, or relapse, rather than routinely for all newly diagnosed patients. The relationship between transplantation and newer immune therapies continues to evolve. T-lineage ALL has fewer established antigen-directed options; nelarabine, a purine nucleoside analogue, has a specific role in T-lineage treatment, while several cellular and targeted strategies remain under investigation."
    },
    {
      "heading": "Treatment complications, supportive care, and survivorship",
      "text": "The intensity and duration of ALL treatment make supportive care a major determinant of outcome. Marrow suppression can produce prolonged neutropenia, anemia, and thrombocytopenia. Bacterial, fungal, and viral infections contribute substantially to treatment-related illness and death. Management within treatment programs includes infection surveillance, antimicrobial prophylaxis in defined settings, and prompt treatment of suspected infection. Prophylaxis against Pneumocystis jirovecii pneumonia is a standard feature of many ALL protocols.\n\nTumor lysis syndrome is an important early metabolic complication, especially with a high leukemia burden or highly treatment-sensitive disease. Clinical protocols use risk assessment, fluid management, laboratory monitoring, and uric-acid-lowering drugs such as allopurinol or rasburicase. Blood transfusion support compensates for inadequate red-cell and platelet production. Central venous access facilitates repeated drug administration and blood sampling but introduces risks of bloodstream infection and thrombosis. Nutritional impairment and oral or gastrointestinal mucosal injury can further complicate treatment delivery.\n\nIndividual drugs have characteristic adverse effects. Asparaginase can cause hypersensitivity, pancreatitis, liver dysfunction, and thrombotic complications. Corticosteroids can produce hyperglycemia, muscle weakness, mood changes, infection susceptibility, and osteonecrosis, the latter particularly important in adolescents. Vincristine can cause peripheral neuropathy and constipation. Methotrexate may produce mucositis, liver abnormalities, kidney injury at high doses, and neurological toxicity. Anthracyclines can injure the heart, with risk influenced by cumulative exposure and other factors.\n\nSurvivorship extends beyond freedom from relapse. Late effects can include cardiomyopathy, reduced bone density, endocrine dysfunction, impaired fertility, subsequent malignancies, and neurocognitive difficulties. Risks depend on the actual treatment received, age at exposure, genetic susceptibility, and complications during therapy. Cranial irradiation and transplantation create different long-term risk profiles from chemotherapy-only regimens. Neurocognitive effects may involve attention, processing speed, and executive function, even when overall intelligence remains within the usual range.\n\nThe prolonged course also affects education, employment, family life, and mental health. Treatment adherence during maintenance is associated with outcome, but missed treatment can reflect medication access, complex schedules, adverse effects, financial pressures, and communication barriers rather than a single behavioral cause. Survivorship programs therefore use treatment-exposure histories to organize follow-up across physical, cognitive, reproductive, and psychosocial domains. Palliative care can accompany disease-directed treatment to address symptoms and family needs; it is not restricted to situations in which leukemia therapy has stopped."
    },
    {
      "heading": "Historical development, outcomes, and current research",
      "text": "Before effective chemotherapy, childhood ALL was usually fatal within months. A major turning point came in 1948, when Sidney Farber and colleagues reported temporary remissions in children treated with the folate antagonist aminopterin. These responses demonstrated that leukemia could be pharmacologically suppressed, but single-drug treatment rarely produced durable control. Subsequent work established combination chemotherapy, treatment beyond apparent remission, and direct attention to sites such as the central nervous system.\n\nDuring the 1960s, programs including the St. Jude “Total Therapy” studies combined multiple treatment principles into curative strategies. Cooperative groups then refined drug combinations, scheduling, risk assignment, and supportive care through large clinical trials. The development of effective central nervous system prophylaxis was particularly important because marrow remission did not prevent meningeal relapse. Later advances reduced cranial irradiation and other exposures in patients who could retain high cure rates with less treatment-related harm.\n\nIn contemporary high-income settings, five-year overall survival for childhood ALL exceeds 90% in many populations and treatment programs. This aggregate conceals meaningful variation by age, subtype, response, and treatment access. Infants and patients with certain adverse genetic features have less favorable outcomes. Adult survival has improved, especially among adolescents and young adults receiving appropriate contemporary regimens, but remains substantially lower overall than childhood survival. Older adults have particularly high competing risks from resistant disease, comorbidity, and treatment toxicity.\n\nRelapse remains a major cause of treatment failure. It may involve marrow, the central nervous system, testes, or more than one site. Prognosis after relapse depends on its timing and location, lineage, molecular features, prior treatment, and the response to salvage therapy. Early marrow relapse is generally less favorable than a later isolated extramedullary relapse. Survival statistics also require careful interpretation: overall survival, event-free survival, relapse-free survival, and treatment-related mortality measure different outcomes, and results from a selected trial population may not represent an entire national population.\n\nCurrent research seeks both more effective treatment and less cumulative harm. Important approaches include introducing immunotherapy earlier, identifying which MRD-negative patients can safely receive less chemotherapy, improving therapy for T-lineage and high-risk genetic subtypes, and preventing antigen escape after cellular therapy. Sequencing and single-cell studies examine how minor leukemic subclones survive treatment and seed relapse. Alongside these biological questions, international treatment programs study adapted regimens, diagnostic capacity, reliable drug supply, and infection support, because the ability to deliver an established protocol safely remains a major source of global outcome differences."
    }
  ],
  "links": [
    "cancer",
    "bone-marrow",
    "t-cell",
    "chemotherapy",
    "lymphoma",
    "chronic-myeloid-leukemia",
    "gene-expression",
    "incidence",
    "dna",
    "acute-myeloid-leukemia",
    "myelodysplastic-syndrome",
    "down-syndrome",
    "anemia",
    "fatigue",
    "fever",
    "lymph-node",
    "spleen",
    "mediastinum",
    "central-nervous-system",
    "meninges",
    "cerebrospinal-fluid",
    "complete-blood-count",
    "biopsy",
    "flow-cytometry",
    "differential-diagnosis",
    "metastasis",
    "corticosteroid",
    "blood-brain-barrier",
    "radiation-therapy",
    "pharmacogenomics",
    "monoclonal-antibody",
    "bispecific-antibody",
    "cytokine-release-syndrome",
    "antibody-drug-conjugate",
    "car-t-cell-therapy",
    "immune-effector-cell-associated-neurotoxicity-syndrome",
    "hematopoietic-stem-cell-transplantation",
    "graft-versus-leukemia-effect",
    "graft-versus-host-disease",
    "neutropenia",
    "blood-transfusion",
    "thrombosis",
    "mental-health",
    "palliative-care",
    "clinical-trial"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}